The facility will produce antibody-drug conjugates and other advanced medicines, with capacity for both active pharmaceutical ingredients and finished products.
The new platform adds amorphous solid dispersion manufacturing to the Couvet site’s existing oral dosage and packaging operations, according to the company.
The teaming with Brazilian partners Bahiafarma and Bionovis includes technology transfer of the biosimilar to support the gradual transition to local manufacturing.
The partnership connects national laboratory research with industry expertise and pilot-scale facilities to support the development of biobased chemicals and materials.
The Frankfurt campus will add active pharmaceutical ingredient capacity, with production planned for 2032, as the company expands its global biologics and vaccine network.
The financing would support U.S. manufacturing of critical pharmaceutical ingredients, building on existing federal-backed efforts to expand biosynthesis production.
The technology transfer will prepare S2N.Bio’s autologous cell therapy for clinical manufacturing ahead of a planned first-in-human trial in 2027 in that country.
